Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Robinhood Markets, Inc. (HOOD) Price & Performance

ADMA Biologics IncTrade
Robinhood Markets, Inc.Trade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Robinhood Markets, Inc. — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while Robinhood Markets, Inc. trades at $93.66 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 38.2× ADMA Biologics Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAHOOD
Market Cap
$2.22B$84.86B
Sector
HealthTechnology
52-Week High
$20.38$152.46
52-Week Low
$7.60$65.16
Enterprise Value
$2.29B$91.40B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Robinhood Markets, Inc.

Robinhood (HOOD) trades at $94.52, up 1.32% in 24 hours, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.62 actual vs. $0.44 expected, and revenue growth of 32% year-over-year. Recent news highlights expansion into UK crypto services and product diversification, though technical indicators suggest caution amid high valuation multiples.

Outlook: Bullish fundamentals with robust revenue growth and profit margins, but elevated P/E of 41.76 poses valuation risk. Opportunities include international expansion and non-crypto revenue streams; risks involve competitive pressures and reliance on market volatility. Analyst consensus price target of $123.46 implies significant upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Robinhood Markets, Inc.

Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.

Read more on HOOD